Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 4,175 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control comparison Clear all

Conditions: Colonoscopy
Interventions: Bowel Prep; Drug
Lead sponsor: Braintree Laboratories; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 34
States / cities: Tucson, Arizona • Little Rock, Arkansas • North Little Rock, Arkansas + 29 more

Conditions: Acute Spinal Cord Injury, Spinal Cord Injuries
Interventions: Measures of spasticity, connectivity and analysis of single nucleotide polymorphisms and biomarkers of inflammation, Analysis of biomarkers; Other
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Dry Eye
Interventions: 0.25% Tanfanercept Ophthalmic Solution, Placebo; Drug
Lead sponsor: HanAll BioPharma Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 10
States / cities: Phoenix, Arizona • Glendale, California • Newport Beach, California + 7 more

Conditions: Body Weight Changes
Interventions: MicroDiet, Healthy Diet; Behavioral
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Bacterial Vaginosis
Interventions: Vaginal acidifying gel (RepHresh), Metronidazole control; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Generalized Anxiety Disorder
Interventions: Placebo, DT120; Other · Drug
Lead sponsor: Definium Therapeutics US, Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 34
States / cities: Gilbert, Arizona • Scottsdale, Arizona • La Jolla, California + 27 more

Conditions: Hepatic Insufficiency, Neoplasms
Interventions: Onureg; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Iowa City, Iowa • Detroit, Michigan • Cleveland, Ohio + 1 more

Conditions: Systemic Lupus Erythematosus
Interventions: Deucravacitinib, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 48
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 42 more

Conditions: Knee Osteoarthritis
Interventions: Micronized dHACM, Saline; Biological · Drug
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 17
States / cities: Birmingham, Alabama • Tempe, Arizona • La Mesa, California + 14 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: BCT197, Placebo; Drug
Lead sponsor: Mereo BioPharma; Industry
Eligibility: 40 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Michigan City, Indiana • Baltimore, Maryland • Milwaukee, Wisconsin

Conditions: Fertility
Interventions: Freezing; Procedure
Lead sponsor: Main Line Fertility Center; Other
Eligibility: 21 Years to 37 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Bryn Mawr, Pennsylvania

Conditions: Menopause
Interventions: Ashoka Bark and Shatavari, Placebo; Dietary Supplement · Other
Lead sponsor: Vidya USA Corporation; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Port Richey, Florida

Conditions: Osteoarthritis
Interventions: Jebsen Taylor Hand function test, Pinch strength, Grooved pegboard test; Diagnostic Test
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Bronchoscopy
Interventions: Remimazolam, Placebo, Midazolam; Drug
Lead sponsor: Paion UK Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 14
States / cities: Brandon, Florida • Sun City Center, Florida • Michigan City, Indiana + 10 more

Conditions: End Stage Renal Disease, Chronic Kidney Disease, Sleep Disorder
Interventions: Melatonin; Drug
Lead sponsor: Southeast Renal Research Institute; Other
Eligibility: 18 Years to 85 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: Neonatal Abstinence Syndrome
Interventions: Stochastic Vibrotactile Stimulation (SVS), Control; Device · Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 1 Day to 1 Year
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec, insulin glargine; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,030 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 86
States / cities: Bay Minette, Alabama • Birmingham, Alabama • Huntsville, Alabama + 80 more

Conditions: Alcohol Use
Interventions: Customizable personalized normative feedback (CPNF), Personalized normative feedback (PNF), Attention-Matched Control (AMC); Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 24 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hypoparathyroidism
Interventions: Canvuparatide, Placebo; Drug · Other
Lead sponsor: MBX Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 21
States / cities: Englewood, Colorado • Homestead, Florida • Lawrenceville, Georgia + 18 more

Conditions: Radon Exposure
Interventions: Radon Risk Messaging Materials; Behavioral
Lead sponsor: Stacy Stanifer; Other
Eligibility: 21 Years to 100 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Opioid Use Disorder
Interventions: buprenorphine; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 41 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Varicose Veins, Venous Insufficiency
Interventions: VNUS RF ClosureFAST, VenaCure EVLT NeverTouch; Device
Lead sponsor: Angiodynamics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 6
States / cities: Sacramento, California • Bradenton, Florida • Melrose Park, Illinois + 3 more

Conditions: Metabolic Syndrome
Interventions: PP-MI Intervention; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 100 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Revere, Massachusetts

Conditions: Asthma
Interventions: tiotropium bromide, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 5
States / cities: Denver, Colorado • Columbia, Missouri • Warrensburg, Missouri + 2 more

Search by objective public record fields.

Study 302: BLI4900 Versus an FDA-approved Comparator in Adult Subjects Prior to Colonoscopy

Spasticity and Functional Recovery After SCI

A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye

The Effects of Formula Diet on Body Weight, Body Composition, and Biomarkers for Disease Compared to a Standard Diet

Recurrent Bacterial Vaginosis and Vaginal Acidifying Gel Trial

A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)

A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies

A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

Micronized dHACM vs. Saline in the Treatment of Osteoarthritis of the Knee

Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease

Effect of Oocyte Vitrification on Fertilization Rate, Embryo Quality and Development

Satavari and Ashoka for Menopause (SAM) Study

Function Following Thumb MP Fusion and IP Fusion

A Phase III Study of Remimazolam in Patients Undergoing Bronchoscopy

Different Doses of Oral Melatonin Supplements in Chronic Kidney Disease (CKD)-Associated Sleep Disorders

Physiology and Therapeutic Management of Neonatal Abstinence Syndrome

Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes

CPNF Intervention Development and Testing

A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism

Radon on the RADAR (Residents Acting to Detect and Alleviate Radon) 2.0

Long Acting Subcutaneous vs Short Acting Sublingual Buprenorphine in Pregnant and Lactating Women

Comparison Study for Safety and Efficacy of Two Devices for the Treatment of the Great Saphenous Vein

Developing a Positive Psychology Intervention to Promote Health Behaviors in Metabolic Syndrome: RCT

Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma